Metabolism of a new antiepileptic drug, N-methyl- tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites

Epilepsy Research

Volumn 58, Issue 1, 2004, Pages 1-12

  Isoherranen, Nina ^a   Levy, René H ^b   Yagen, Boris ^a,c   Woodhead, José H ^d   White, H Steve ^d   Bialer, Meir ^a,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

6 Hz seizures; Anticonvulsant activity; Cytochrome P450; Human liver microsomes; N Hydroxymethyl tetramethylcyclopropanecarboxamide; N Methyl tetramethylcyclopropanecarboxamide

Indexed keywords

ACETONITRILE; ANTICONVULSIVE AGENT; CHLORZOXAZONE; COMPLEMENTARY DNA; CYTOCHROME P450; DRUG METABOLITE; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; METHOXSALEN; N DEMETHYLASE; N HYDROXYMETHYL TETRAMETHYLCYCLOPROPANECARBOXAMIDE; N METHYL TETRAMETHYLCYCLOPROPANECARBOXAMIDE; PENTETRAZOLE; PILOCARPINE; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TETRAMETHYLCYCLOPROPANECARBOXAMIDE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; WARFARIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG METABOLISM; DRUG POTENCY; ELECTROCONVULSIVE THERAPY; EPILEPSY; EPILEPTIC DISCHARGE; FEMALE; HUMAN; HYDROXYLATION; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

AMIDES; ANIMALS; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; BEHAVIOR, ANIMAL; BIOTRANSFORMATION; BRAIN; BRAIN CHEMISTRY; CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; MALE; MICE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PENTYLENETETRAZOLE; SEIZURES; VALPROIC ACID;

EID: 1842556076     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2003.12.001     Document Type: Article

References (27)

1. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 47:2001;217-227.
2. Bialer M., Hadad S., Kadry B., Abdul-Hai A., Haj-Yehia A., Sterling J., Herzig Y., Yagen B. Pharmacokinetic analysis and antiepileptic activity of tetramethylcyclopropane analogues of valpromide. Pharm. Res. 13:1996;284-289.
3. Blotnik S., Bergman F., Bialer M. Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. Eur. J. Pharm. Sci. 6:1998;93-98.
4. Bourgeois, B.F.D., 2002. Valproic acid: efficacy and use in epilepsy. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E., (Eds.), Antiepileptic Drugs, 5th ed. Lippincott Williams and Wilkins, pp. 808-827.
5. Bourrie M., Meunier V., Berger Y., Fabrez G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
6. Chauret N., Gauthier A., Nicol-Griffith D.A. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab. Dispos. 26:1998;1-4.
7. Estabrook R.W., Peterson J., Baron J., Hildebrandt A. The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism. Methods Pharmacol. 2:1972;303-3501.
8. Finney, D.J., 1971. Probit Analysis, 3rd ed. Cambridge University Press, Cambridge, UK.
9. Genton, P.P., Gelisse, P., 2002. Valproic acid: adverse effects. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca, E. (Eds.), Antiepileptic Drugs, 5th ed. Lippincott Williams and Wilkins, pp. 837-851.
10. Hickman D., Wang J.-P., Wang Y., Unadkat J.D. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab. Disposit. 26:1998;207-215.
11. Isoherranen N., White H.S., Finnell R.H., Yagen B., Woodhead J.H., Bennett G.D., Wilcox K.S., Barton M.E., Bialer M. Anticonvulsant profile and teratogenicity of N-methyltetramethylcyclopropane carboxamide: a new antiepileptic drug. Epilepsia. 42:2002;115-126.
12. Isoherranen N., Yagen B., Bialer M. New CNS-active drugs which are second generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol. 16:2003;203-211.
13. Kaneko K., Battino D., Anderman E., Wada K., Kan R., Takeda A., Nakane Y., Ogawa Y., Avanzini G., Fumarola C., Granata T., Molteni F., Pardi G., Minotti L., Canger R., Dansky L., Oguni M., Lopes-Cendas I., Sherwin A., Anderman F., Seni M.-H., Okada M., Teranishi T. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 33:1999;145-158.
14. Kunze K., Wienkers L.C., Thummel K.E., Trager W.F. Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependant metabolism of warfarin by fluconazole: in vitro studies. Drug Metab. Dispos. 24:1996;414-421.
15. Lothman E.W., Williamson J.M. Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: a rapid developing transient kindling and a slowly developing enduring kindling. Brain Res. 649:1988;71-84.
16. Newton D.J., Wang R.W., Lu A.Y.H. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 23:1995;154-158.
17. Paine M.F., Khalighi M., Fisher J.M., Shen D.D., Kunze K.L., Marsh C.L., Perkins J.P., Thummel K.E. Characterization of inter- and intra-intestinal differences in human CYP3A-dependant metabolism. J. Pharmacol. Exp. Ther. 283:1997;1552-1562.
18. Perucca E. Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs. 16:2002;695-714.
19. Peter R., Bocker R., Beaune P.H., Iwasaki M., Guengerich F.P., Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3:1990;566-573.
20. Ross D., Farmer P.B., Gescher A., Hickman J.A., Threadgill M.D. The formation and metabolism of N-hydroxymethyl compounds-III. The metabolic conversion of N-methyl and N,N-dimethylbenzamides to N-hydroxymethyl-compounds. Biochem. Pharmacol. 32:1983;1773-1781.
21. Rosseel M., Belpaire F.M., Samijn N., Wijnant P. Simultaneous determination of N,N-dimethylformamide, N-monomethylformamide and N-hydroxymethyl-N-methylformamide in rat plasma by capillary gas chromatography. J. Chromatogr. 615:1993;154-158.
22. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., Hulse J.D., McGilveray I.J., McKay C., Miller K.J., Patnaik R.N., Powell M.L., Tonell A., Viswanathan C.T., Yacobi A. Bioanalytical method validation - a revisit with decade of progress. Pharm. Res. 17:2000;1551-1557.
23. Taylor W.G., Hall T.W., Vedres D.D. Metabolites of N-ethylbenzamide, N,N-diethylbenzamide and related compounds detected in rat urine by NMR spectroscopy. Drug Metab. Dipos. 23:1995;1188-1194.
24. Voirol P., Jonzier-Perey M., Porchet F., Reymond M.J., Janzer R.C., Bouras C., Strobel H.W., Kodel M., Eap C.B., Baumann P. Cytochrome P-450 activities in human and rat brain microsomes. Brain. Res. 855:2000;235-243.
25. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 38(Suppl. 1):1997;S9-S17.
26. White, H.S., Woodhead, J.H., Wilcox, K.S., Stables, J.P., Kupferberg, H.J., Wolf, H.H., 2002. General principles: discovery and preclinical development of antiepileptic drugs. In: Levy, R.H., Mattson, R.H., Meldrum, B.S., Perucca E. (Eds.), Antiepileptic Drugs, 5th ed. Lippincott Williams and Wilkins, pp. 36-48.
27. Zhang W., Kilicarslan T., Tyndale R.F., Sellers E.M. Evaluation of methoxsalen, tranylcypromine and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab. Dispos. 26:2001;897-902.